AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

OCUL · NASDAQ · Biotechnology

Ocular Therapeutix (OCUL)

Develops hydrogel-delivered retinal therapies and commercial ophthalmic drug inserts.

$9.89

vs last close−0.61 (−5.82%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	15	15	15	16	15	17	11	13	15	13	11	13
Cost of revenue	1	1	1	2	2	1	1	2	2	2	1	2
Gross profit	14	13	13	15	14	16	9	12	13	12	9	11
	33	33	45	59	60	66	73	79	81	81	103	94
Research & development	15	16	21	29	37	41	43	51	52	51	66	54
	18	17	24	30	23	25	30	28	29	31	37	39
Selling & marketing	1	−26	1	10	11	1	2	2	13	13	17	17
General & administrative	17	44	23	20	12	24	29	27	16	18	20	22
Operating income	−19	−20	−32	−44	−46	−51	−64	−68	−69	−70	−93	−82
	19	−9	−33	0	10	2	0	0	−1	5	5	3
Interest income	1	1	4	6	6	5	4	3	4	7	6	5
Interest expense	3	4	4	3	3	3	3	3	3	3	3	3
Other non-operating income	−22	5	29	−3	−13	−5	−3	−3	−2	−8	−8	−6
Income before tax	−1	−29	−65	−44	−36	−48	−64	−68	−69	−65	−89	−79
Net income from continuing operations	−1	−29	−65	−44	−36	−48	−64	−68	−69	−65	−89	−79
Net income	−1	−29	−65	−44	−36	−48	−64	−68	−69	−65	−89	−79
EPS, basic	−$0.27	−$0.21	−$0.49	−$0.26	−$0.22	−$0.29	−$0.38	−$0.39	−$0.38	−$0.29	−$0.40	−$0.35
EPS, diluted	−$0.25	−$0.20	−$0.49	−$0.26	−$0.22	−$0.29	−$0.38	−$0.39	−$0.38	−$0.29	−$0.40	−$0.35
Weighted average shares, basic	79	106	132	166	167	168	169	173	184	223	224	225
Weighted average shares, diluted	85	109	132	166	167	168	169	173	184	223	224	225
EBITDA	4	−24	−60	−40	−32	−44	−60	−64	−65	−61	−85	−74
Depreciation & amortization	1	1	1	1	1	1	1	1	1	1	1	2
EBIT	3	−25	−61	−41	−33	−45	−61	−65	−66	−62	−86	−76